Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

Regulatory T cells (Tregs) represent a major obstacle of cancer immunotherapy. We reviewed here our discovery that Class I histone deacetylase (HDAC) inhibition can functionally target Tregs and help break the immune tolerance. We also discuss the effects of different classes of HDAC inhibitors on T...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Li, Pili, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489755/
https://www.ncbi.nlm.nih.gov/pubmed/23162767
http://dx.doi.org/10.4161/onci.20306
_version_ 1782248775729807360
author Shen, Li
Pili, Roberto
author_facet Shen, Li
Pili, Roberto
author_sort Shen, Li
collection PubMed
description Regulatory T cells (Tregs) represent a major obstacle of cancer immunotherapy. We reviewed here our discovery that Class I histone deacetylase (HDAC) inhibition can functionally target Tregs and help break the immune tolerance. We also discuss the effects of different classes of HDAC inhibitors on Tregs and the underline mechanisms, which may have a direct impact on designing cancer immunotherapy trials involving HDAC inhibitors.
format Online
Article
Text
id pubmed-3489755
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-34897552012-11-16 Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy Shen, Li Pili, Roberto Oncoimmunology Author's View Regulatory T cells (Tregs) represent a major obstacle of cancer immunotherapy. We reviewed here our discovery that Class I histone deacetylase (HDAC) inhibition can functionally target Tregs and help break the immune tolerance. We also discuss the effects of different classes of HDAC inhibitors on Tregs and the underline mechanisms, which may have a direct impact on designing cancer immunotherapy trials involving HDAC inhibitors. Landes Bioscience 2012-09-01 /pmc/articles/PMC3489755/ /pubmed/23162767 http://dx.doi.org/10.4161/onci.20306 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Shen, Li
Pili, Roberto
Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
title Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
title_full Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
title_fullStr Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
title_full_unstemmed Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
title_short Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
title_sort class i histone deacetylase inhibition is a novel mechanism to target regulatory t cells in immunotherapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489755/
https://www.ncbi.nlm.nih.gov/pubmed/23162767
http://dx.doi.org/10.4161/onci.20306
work_keys_str_mv AT shenli classihistonedeacetylaseinhibitionisanovelmechanismtotargetregulatorytcellsinimmunotherapy
AT piliroberto classihistonedeacetylaseinhibitionisanovelmechanismtotargetregulatorytcellsinimmunotherapy

Ejemplares similares